ClinicalTrials.gg
CompletedNCT05286762Updated Jan 22, 2026Results posted

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

A Phase 3 interventional study of CTx-1301-Dexmethylphenidate 12.5 mg (titration only) and CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose) in ADHD, Attention Deficit Hyperactivity Disorder and ADHD - Combined Type, sponsored by Cingulate Therapeutics. Completed at 24 sites in United States. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-01-22.

Sponsored by Cingulate Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
103
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.

Enrollment
283rd of 706
103 · median 70
Started
2023
with 29 others
Phase 3
121 of 807
4 open now
Registered
654th of 807
by date

Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 283rd largest by enrollment of the 706 interventional ones that give a count, is one of 30 that started in 2023, is one of 121 in phase 3, and was the 654th registered.

Attention Deficit Disorder with Hyperactivity

1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.

Browse Attention Deficit Disorder with Hyperactivity studies →

Open to participants now

98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, or all of them as a file.
02

Study summary

A Phase 3, randomized, double-blind, placebo-controlled, multi-center, fixed-dose, parallel-group efficacy and safety study in a pediatric population (6-17) with Attention-Deficit/Hyperactivity Disorder (ADHD) using CTx-1301 (d-MPH). The study will be comprised of a screening period, a double-blind randomized phase, and a safety follow-up visit.

Read the detailed description

A Phase 3, double-blind, randomized, placebo-controlled, multi-center, fixed-dose, parallel group efficacy and safety study in pediatrics (6-17) with ADHD diagnosis confirmed by an ADHD-RS-5 score of at least 28 and CGI-S score of at least 4 (moderately ill) at screening. The study will be comprised of a screening period, a double-blind randomized phase, and a safety follow-up visit.

The Study will be comprised of 3 periods:

  • Screening Period (Day -30 to Day -1): Subjects will undergo a Screening Visit (Visit 1) up to 30 days prior to entering the randomized treatment period. Only subjects that meet all inclusion and no exclusion criteria at screening may be considered for entry/randomization into the study. A reminder telephone call will be completed 5 days prior to Day 0 (Visit 2) to ensure washout of current prohibited medications, to confirm inclusion/exclusion criteria, and to confirm date of next visit.
  • Randomized Treatment Period (Day 0 to Day 35 +/- 3 days): Subjects will be randomized on Day 0 to active or placebo (placebo, CTx-1301 18.75 mg, CTx-1301 25 mg, or CTx-1301 37.5 mg). Subjects randomized to the active dose will have a starting dose of 12.5 mg on Day 0. Each subject randomized to an active dose will be titrated (increased) weekly until they reach their assigned fixed dose; subjects must be on their assigned fixed dose a minimum of 2 sequential weeks prior to the primary efficacy assessment at Week 5/Visit 8. Subjects will be instructed to take their dose every morning at-home upon waking, no later than 8:00 am.
  • Safety Follow-Up Visit (Day 42 +/- 5 days): Subjects will be evaluated for safety after washout of medication.

Subjects will participate in the study as outpatients for up to approximately 10 weeks (including screening); a 30-day screening period, a 5-week double-blind randomized period, and a 1-week follow-up safety visit.

Completion of the primary study is defined as LSLV at Visit 9.

Subjects will be randomized at baseline to CTx-1301 or placebo (CTx-1301 18.75 mg, CTx-1301 25 mg, CTx-1301 37.5 mg, or placebo). Starting dose for subjects randomized to active treatment is 12.5 mg. These subjects will then be titrated up to their assigned fixed dose (18.75, 25, or 37.5 mg) for the last two weeks of the study period. Subjects randomized to placebo will receive placebo treatment for the full 5 weeks of the study.

Sparse PK sampling will be conducted after a single dose and at steady state from the patient population with special attention given to the time the sample is obtained post-dose. These analyses will inform strategies that manage dosing and detail administration for a given subpopulation, planned subsequent studies, and support labeling.

03

Conditions studied

  • ADHD
  • Attention Deficit Hyperactivity Disorder
  • ADHD - Combined Type
  • Attention Deficit Hyperactivity Disorder Combined
  • Attention-deficit Hyperactivity
  • Attention Deficit Hyper Activity

Keywords

  • ADHD
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subjects between 6 and 17 years of age (inclusive) at the time of Randomization (Visit 2). Subjects who are expected to turn 18 years of age during the trial will not be allowed.
  2. Subject must have a body weight between the 5th and 95th percentile (≥5th percentile and ≤95th percentile) for their respective age and sex.
  3. Subject is unsatisfied with his/her current pharmacological therapy for treatment of ADHD or not currently receiving pharmacological therapy for ADHD. Inclusion of subjects who are naïve to pharmacological therapy for ADHD is permitted.
  4. Subjects of at screening or that become of child-bearing potential during the study must agree to remain abstinent or agree to use a highly effective, medically acceptable form of for the time of written assent and for at least 30 days after the last dose of study drug has been taken (females). Male subjects with female partners must agree at Screening to remain abstinent or agree to use an effective and medically acceptable form of birth control from Screening to 90 days after the last dose of study drug. Child-bearing potential is defined as any female who has had their first period or is 12 years or older (or will be 12 while in the study).
  5. Subject must be in general good health defined as absence of any abnormalities as determined by the Investigator based on physical and neurological examinations, vital signs, ECGs ( less than or equal to 460 milliseconds), medical history, and laboratory values (hematology, chemistry, serology, TSH, or urinalysis) at Screening. If any of the exams or values are not within the laboratory reference range, the Investigator must review range and determine if clinically relevant. If clinically relevant, the subject is not eligible for the study.
  6. Subject's intellectual function is at an age-appropriate level, as deemed by the Investigator.
  7. Subject must meet - Fifth Edition (DSM-5) criteria for the primary diagnosis of ADHD or any of the three presentations (combined, inattentive, or hyperactive/impulsive presentation) upon clinical evaluation and confirmed by the MINI International Neuropsychiatric Interview of Children and Adolescents (MINI-KID). The MINI should also be used to evaluate any other psychotic disorders.
  8. Subject must score 28 or higher on the ADHD-RS-5 scale at the Baseline visit (Visit 2).
  9. Subject must have a score of 4 (moderately ill) or higher on the clinician-administrated Clinical Global Impressions-Severity (CGI-S) scale at Baseline (Visit 2).
  10. Subject must be able and willing to wash out of stimulant ADHD medications (except study drug as indicated per protocol), including herbal medication, from 5 days prior to the start of the randomized phase (Visit 2) and for the duration of the entire study, defined as completion of the safety follow-up visit (approximately 1.25 months, excluding screening). Additionally, subject must be able and willing to wash out from non-stimulant ADHD medications 21 days prior to the start of the randomized phase (Visit 2) and for the duration of the entire study (approximately 1.25 months, excluding screening), defined as completion of the safety follow-up visit.
  11. Subject and parent/legal guardian, and/or caregiver (if applicable) must be able to read, write, speak, and understand English and be able to communicate with the Investigator and study coordinator in a satisfactory fashion and complete any study-related materials. Subject and parent/legal guardian, and/or caregiver (if applicable) must plan to be available for the entire duration of the study.
  12. One or more of the parents/legal guardians/caregivers of the subject must voluntarily give written permission for him/her to participate in the study.
  13. Subject must provide written assent prior to study participation.
  14. Subject, subject's parent/legal guardian, and/or caregiver (if applicable) must understand and be willing and able to comply with study procedures as well as the visit schedule. If the subject is cared for by a caregiver for relevant portions of the day, the caregiver may be more suitable for certain assessments, and the caregiver will need to agree to the applicable procedures and visits.
  15. Subject must be able to swallow the CTx-1301 tablet as evidenced by ability to swallow a similar size tablet (placebo) at screening.

Exclusion criteria

Exclusion Criteria:

  1. If female and of , the subject must not be pregnant or breastfeeding at any time during the study or for 30 days following the completion of the study, defined as completion of safety visit at the end of study (Visit 9). If of child-bearing potential, urine hCG tests will be administered at protocol-specified time points. Any positive pregnancy test during the study will exclude them from further participation in the study.
  2. Subject has any psychiatric diagnosis of bipolar I or II disorder, major depressive disorder, conduct disorder, disruptive mood dysregulation disorder (DMDD), intellectual disability, obsessive-compulsive disorder, eating disorder, anxiety disorder (including generalized anxiety disorder), any history of psychosis, autism spectrum disorder, a history of motor or vocal tics or Tourette's Syndrome, confirmed genetic disorder with cognitive and/or behavioral disturbances, or any other diagnosis/significant medical history that at the discretion of the Investigator excludes the subject from entry into the study.
  3. Subject has evidence of any chronic disease of the central nervous system (CNS) such as tumors, inflammation, seizure disorder, vascular disorder, potential CNS-related disorders that might occur in childhood, or history of persistent neurological symptoms related to a serious head injury.
  4. Subject has any and/or unstable/uncontrolled medical abnormality or chronic medical condition, persistent neurological symptoms, history of cardiovascular abnormality, abnormalities of respiratory, hepatic, gastrointestinal, renal, or any disorder or history of a condition that would impact or interfere with drug absorption, distribution, metabolism, or excretion during the study or may interfere with the participants ability to participate in the study.
  5. Subject has family history of early cardiovascular disease or sudden death.
  6. Subject has any history of attempted suicide or clinically significant suicidal ideation based on the Columbia Suicide Severity Rating Scale (C-SSRS) assessment, or answers "yes" to "Suicidal Ideation" item 4 or 5 of any lifetime history on the C-SSRS Children's Lifetime/Recent assessment at screening.
  7. Subject has history of seizures, excluding febrile seizures.
  8. Subject has a known primary sleep disorder (e.g., sleep apnea, narcolepsy, etc.)
  9. If the subject's blood pressure is \< 90th percentile for their age, sex, and height, the single read is sufficient. If the subject's blood pressure is ≥ 90th percentile, two additional reads will be taken, and the three reads will be averaged. If the average of the three readings is ≥ 95th percentile at screening they will be excluded.
  10. Subject is considered treatment by the Investigator or is intolerant to stimulant ADHD mediation.
  11. Any use of anticonvulsants currently or within the past 2 years.
  12. Uncontrolled thyroid disorder indicated by thyroid stimulating hormone (TSH) ≤0.8 x the lower limit of normal (LLN) or ≥ 1.25 x the (ULN) from the reference laboratory.
  13. Subject has first-degree relatives (biological parent or sibling) with a history of schizophrenia, schizoaffective disorder, bipolar I disorder, or bipolar II disorder.
  14. Subject has history of substance abuse or shows evidence of substance use or has a positive urine drug screen at Screening or Baseline. Subjects with positive drug screens may be allowed to continue in the study if the result of the positive drug screen is from prescribed medications and the subject is willing to washout of the medication as required per protocol.
  15. Previous treatment experience/exposure to CTx-1301.
  16. Subject has a history of allergic reaction or sensitivity to methylphenidate, dexmethylphenidate, or any other substance contained in CTx-1301 or the placebo drug.
  17. Subject has participated in any other clinical study with an drug/product within 30 days prior to Screening or is currently participating in another clinical study.
  18. Subject's family anticipates a move outside the geographic range of the investigative site during the duration of the study period or plans on travel that would not allow compliance to the protocol during the study period.
  19. Subject is unsuitable in any other way, to participate in the study, as determined by the Investigator.
  20. Subject is a family member of an employee at the study center, of the investigator, or those with direct involvement in the proposed study under the direction of that investigator or study center.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
103 participants (actual)

Study arms

  • Active comparator
    18.75 mg CTx-1301 (dexmethylphenidate tablet)

    Subjects who are randomized to active drug (18.75 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to their assigned dose of 18.75 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.

    Drug: CTx-1301-Dexmethylphenidate 12.5 mg (titration only) · Drug: CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose)

  • Active comparator
    25 mg CTx-1301 (dexmethylphenidate tablet)

    Subjects who are randomized to active drug (25 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to 18.75 mg; at week 2 they will be increased to their assigned dose of 25 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.

    Drug: CTx-1301-Dexmethylphenidate 12.5 mg (titration only) · Drug: CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose) · Drug: CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose)

  • Active comparator
    37.5 mg CTx-1301 (dexmethylphenidate tablet)

    Subjects who are randomized to active drug (37.5 mg of CTx-1301) will be titrated (increased) weekly up to their assigned fixed dose. The starting dose at Day 0 is 12.5 mg; at week 1 they will be increased to 18.75 mg; at week 2 they will be increased to 25 mg; at week 3 they will be increased to their assigned dose of 37.5 mg. Subjects will remain on this assigned fixed dose for the remainder of the randomized study period.

    Drug: CTx-1301-Dexmethylphenidate 12.5 mg (titration only) · Drug: CTx-1301-Dexmethylphenidate 18.75mg (randomized fixed dose) · Drug: CTx-1301-Dexmethylphenidate 25mg (randomized fixed dose) · Drug: CTx-1301-Dexmethylphenidate 37.5 mg (randomized fixed dose)

  • Placebo comparator
    Placebo

    Subjects randomized to placebo will be on placebo for the full 5 weeks of the study.

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Attention Deficit Hyperactivity Disorder Rating Scale 5 (ADHD-RS-5) Scores to ADHD-RS-5 at Visit 8.

    The Attention Deficit Hyperactivity Disorder Rating Scale Version 5 (ADHD-RS-5) overall scores range from 0-54; an improvement from Baseline is defined as a decrease in the overall score.

    Time frame: Baseline (Day 0) to Week 5 (Visit 8)

Secondary outcomes

  1. The Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Clinical Global Impression - Severity (CGI-S) Scores to CGI-S at Visit 8.

    The Clinical Global Impression - Severity (CGI-S) is a single score ranging from 1-7; an improvement from Baseline is defined as a decrease in the score.

    Time frame: Baseline (Day 0) to Week 5 (Visit 8)

  2. Safety - Number of Subjects With Clinically Significant Changes in Vital Signs That Resulted in an Adverse Event.

    Vital signs will be evaluated in each in-office visit; clinically significant changes will be recorded as an adverse event.

    Time frame: Baseline to Visit 8 (5 weeks)

  3. Safety - Number of Subjects With Clinically Significant Changes in Blood Labs That Resulted in an Adverse Event.

    Safety labs will be taken at Screening to determine eligibility for entry into the study; safety labs are assessed again at Visit 8 and any clinically significant change from Screening labs will be recorded as an adverse event.

    Time frame: Screening to Visit 8 (approximately 5-9 weeks, depending on screening window)

  4. Safety - Number of Subjects With Clinically Significant Changes in Physical Exam Findings That Resulted in an Adverse Event.

    Physical exams will be conducted at Screening, Baseline, and Visit 8. Changes noted as clinically significant from Baseline to Visit 8 will be recorded as an adverse event.

    Time frame: Baseline to Visit 8 (5 weeks)

  5. Safety - Number of Subjects With Clinically Significant Changes in Height and Weight BMI That Resulted in an Adverse Event.

    Height and Weight (BMI) will be evaluated at all in-office visits. Any clinically significant change in BMI from Baseline to Visit 8 will be recorded as an AE.

    Time frame: Baseline to Visit 8 (5 weeks)

  6. Safety - Number of Subjects With Clinically Significant Changes in C-SSRS Findings That Resulted in an Adverse Event.

    C-SSRS will be conducted at all in-office visits. Any clinically significant change from Baseline (at any visit) will be reported as an AE.

    Time frame: Baseline to Visit 8 (5 weeks)

  7. Safety - Number of Subjects With Clinically Significant Changes in ECG Findings That Resulted in an Adverse Event.

    ECGs will be taken at Screening to determine eligibility for entry into the study; ECGs are assessed again at Visit 8 and any clinically significant change from Screening ECG will be recorded as an adverse event.

    Time frame: Screening to Visit 8 (approximately 5-9 weeks, depending on screening window)

  8. Safety - Incidence of TEAEs

    Treatment Emergent Adverse Events will be evaluated at each visit.

    Time frame: Screening to Visit 9 (approximately 6-10 weeks, depending on screening window)

07

Results

Posted Jan 22, 2026

Participant flow

Although approximately 385 subjects were expected to enroll in the study, the study was completed with 103 subjects enrolled after an agreement was reached with FDA on the requirements necessary for filing an NDA for CTx-1301. Subjects were recruited at 24 sites from August 1, 2023 to December 13, 2023.

Participant flow — Overall Study
Milestone18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)Placebo
Started26262526
Completed21242122
Not completed5244

Outcome measures

PrimaryThe Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Attention Deficit Hyperactivity Disorder Rating Scale 5 (ADHD-RS-5) Scores to ADHD-RS-5 at Visit 8.

The Attention Deficit Hyperactivity Disorder Rating Scale Version 5 (ADHD-RS-5) overall scores range from 0-54; an improvement from Baseline is defined as a decrease in the overall score.

Time frame:
Baseline (Day 0) to Week 5 (Visit 8)
Reported as:
Mean · score on a scale
The Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Attention Deficit Hyperactivity Disorder Rating Scale 5 (ADHD-RS-5) Scores to ADHD-RS-5 at Visit 8.
score on a scale18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)Placebo
The Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Attention Deficit Hyperactivity Disorder Rating Scale 5 (ADHD-RS-5) Scores to ADHD-RS-5 at Visit 8.-18.0 ± 12.24-17.8 ± 12.78-22.0 ± 15.07-8.1 ± 13.88
SecondaryThe Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Clinical Global Impression - Severity (CGI-S) Scores to CGI-S at Visit 8.

The Clinical Global Impression - Severity (CGI-S) is a single score ranging from 1-7; an improvement from Baseline is defined as a decrease in the score.

Time frame:
Baseline (Day 0) to Week 5 (Visit 8)
Reported as:
Mean · score on a scale
The Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Clinical Global Impression - Severity (CGI-S) Scores to CGI-S at Visit 8.
score on a scale18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)Placebo
The Primary Efficacy Analysis Will Analyze the Mean Change From Baseline (Pre-dose) at Visit 2 of Clinical Global Impression - Severity (CGI-S) Scores to CGI-S at Visit 8.-1.5 ± 1.33-1.5 ± 1.22-2.2 ± 1.57-0.8 ± 1.34
SecondarySafety - Number of Subjects With Clinically Significant Changes in Vital Signs That Resulted in an Adverse Event.

Vital signs will be evaluated in each in-office visit; clinically significant changes will be recorded as an adverse event.

Time frame:
Baseline to Visit 8 (5 weeks)
Reported as:
Count of participants · Participants
Safety - Number of Subjects With Clinically Significant Changes in Vital Signs That Resulted in an Adverse Event.
Participants18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)Placebo
Safety - Number of Subjects With Clinically Significant Changes in Vital Signs That Resulted in an Adverse Event.2231
SecondarySafety - Number of Subjects With Clinically Significant Changes in Blood Labs That Resulted in an Adverse Event.

Safety labs will be taken at Screening to determine eligibility for entry into the study; safety labs are assessed again at Visit 8 and any clinically significant change from Screening labs will be recorded as an adverse event.

Time frame:
Screening to Visit 8 (approximately 5-9 weeks, depending on screening window)
Reported as:
Count of participants · Participants
Safety - Number of Subjects With Clinically Significant Changes in Blood Labs That Resulted in an Adverse Event.
Participants18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)Placebo
Safety - Number of Subjects With Clinically Significant Changes in Blood Labs That Resulted in an Adverse Event.0011
SecondarySafety - Number of Subjects With Clinically Significant Changes in Physical Exam Findings That Resulted in an Adverse Event.

Physical exams will be conducted at Screening, Baseline, and Visit 8. Changes noted as clinically significant from Baseline to Visit 8 will be recorded as an adverse event.

Time frame:
Baseline to Visit 8 (5 weeks)
Reported as:
Count of participants · Participants
Safety - Number of Subjects With Clinically Significant Changes in Physical Exam Findings That Resulted in an Adverse Event.
Participants18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)Placebo
Safety - Number of Subjects With Clinically Significant Changes in Physical Exam Findings That Resulted in an Adverse Event.1114178
SecondarySafety - Number of Subjects With Clinically Significant Changes in Height and Weight BMI That Resulted in an Adverse Event.

Height and Weight (BMI) will be evaluated at all in-office visits. Any clinically significant change in BMI from Baseline to Visit 8 will be recorded as an AE.

Time frame:
Baseline to Visit 8 (5 weeks)
Reported as:
Count of participants · Participants
Safety - Number of Subjects With Clinically Significant Changes in Height and Weight BMI That Resulted in an Adverse Event.
Participants18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)Placebo
Safety - Number of Subjects With Clinically Significant Changes in Height and Weight BMI That Resulted in an Adverse Event.0020
SecondarySafety - Number of Subjects With Clinically Significant Changes in C-SSRS Findings That Resulted in an Adverse Event.

C-SSRS will be conducted at all in-office visits. Any clinically significant change from Baseline (at any visit) will be reported as an AE.

Time frame:
Baseline to Visit 8 (5 weeks)
Reported as:
Count of participants · Participants
Safety - Number of Subjects With Clinically Significant Changes in C-SSRS Findings That Resulted in an Adverse Event.
Participants18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)Placebo
Safety - Number of Subjects With Clinically Significant Changes in C-SSRS Findings That Resulted in an Adverse Event.0010
SecondarySafety - Number of Subjects With Clinically Significant Changes in ECG Findings That Resulted in an Adverse Event.

ECGs will be taken at Screening to determine eligibility for entry into the study; ECGs are assessed again at Visit 8 and any clinically significant change from Screening ECG will be recorded as an adverse event.

Time frame:
Screening to Visit 8 (approximately 5-9 weeks, depending on screening window)
Reported as:
Count of participants · Participants
Safety - Number of Subjects With Clinically Significant Changes in ECG Findings That Resulted in an Adverse Event.
Participants18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)Placebo
Safety - Number of Subjects With Clinically Significant Changes in ECG Findings That Resulted in an Adverse Event.1211
SecondarySafety - Incidence of TEAEs

Treatment Emergent Adverse Events will be evaluated at each visit.

Time frame:
Screening to Visit 9 (approximately 6-10 weeks, depending on screening window)
Reported as:
Count of participants · Participants
Safety - Incidence of TEAEs
Participants18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)Placebo
Safety - Incidence of TEAEs1391710

Adverse events

Collected over Day -30 to Day 42. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
18.75 mg CTx-1301 (Dexmethylphenidate Tablet)0/26 (0%)0/26 (0%)13/26 (50%)
25 mg CTx-1301 (Dexmethylphenidate Tablet)0/26 (0%)0/26 (0%)9/26 (34.6%)
37.5 mg CTx-1301 (Dexmethylphenidate Tablet)0/25 (0%)0/25 (0%)17/25 (68%)
Placebo0/26 (0%)0/26 (0%)10/26 (38.5%)
Most frequent other events
Showing 10 of 48
Most frequent other events
Event18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)Placebo
Decreased appetiteMetabolism and nutrition disorders3/265/267/250/26
Abdominal pain upperGastrointestinal disorders1/261/264/252/26
HeadacheNervous system disorders3/260/261/253/26
Blood pressure increasedInvestigations1/260/262/251/26
Weight decreasedInvestigations0/260/262/250/26
NasopharyngitisInfections and infestations0/260/261/252/26
AnxietyPsychiatric disorders0/262/260/250/26
IrritabilityPsychiatric disorders0/262/260/250/26
TachycardiaCardiac disorders1/262/261/250/26
DyspepsiaGastrointestinal disorders0/260/261/250/26

Baseline characteristics

Age, Customized
Age, Customized(Participants)18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)PlaceboTotal
6-12 Years1616161664
13-17 Years101091039
Sex: Female, Male
Sex: Female, Male(Participants)18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)PlaceboTotal
Female13109941
Male1316161762
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)PlaceboTotal
Hispanic or Latino634619
Not Hispanic or Latino2023212084
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)PlaceboTotal
American Indian or Alaska Native00000
Asian01001
Native Hawaiian or Other Pacific Islander00000
Black or African American1212141351
White1111111245
More than one race32016
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)PlaceboTotal
United States26262526103
BMI Z-Score
BMI Z-Score(Z-Score)18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)PlaceboTotal
Mean0.413 ± 0.83400.221 ± 1.02050.314 ± 1.19930.315 ± 0.93240.315 ± 0.9909
BMI Percentile
BMI Percentile(Percentile)18.75 mg CTx-1301 (Dexmethylphenidate Tablet)25 mg CTx-1301 (Dexmethylphenidate Tablet)37.5 mg CTx-1301 (Dexmethylphenidate Tablet)PlaceboTotal
Mean62.84 ± 27.21256.31 ± 31.41062.40 ± 31.39360.18 ± 29.30960.41 ± 29.538
08

Study locations

24 sites
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Meridien Research
    Maitland, Florida 32751, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Sisu Bhr, Llc
    Springfield, Massachusetts 01103, United States
  • Neurobehavioral Medicine Group
    Bloomfield Hills, Michigan 48302, United States
  • St Charles Psychiatric Associates & Midwest Research Group
    Saint Charles, Missouri 63304, United States
  • Center for Psychiatry and Behavioral Medicine. Inc.
    Las Vegas, Nevada 89128, United States
  • Hassman Research Institute
    Berlin, New Jersey 08009, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Dayton Clinical Research
    Dayton, Ohio 45409, United States
  • SP Research PLLC
    Oklahoma City, Oklahoma 73112, United States
  • Summit Research Network, LLC
    Portland, Oregon 97210, United States
  • Coastal Pediatric Associates
    Charleston, South Carolina 29414, United States
  • Coastal Carolina Research Center
    North Charleston, South Carolina 29405, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • Access Clinical Trials Inc.
    Nashville, Tennessee 37203, United States
  • BioBehavioral Research of Austin
    Austin, Texas 78759, United States
  • Gadolin Research
    Beaumont, Texas 77702, United States
  • Houston Clinical Trials
    Bellaire, Texas 77401, United States
  • FutureSearch Trials
    Dallas, Texas 75231, United States
  • Red Oak Psychiatry Associates, PA
    Houston, Texas 77090, United States
  • Family Psychiatry of The Woodlands
    Woodland, Texas 77381, United States
  • Clinical Research Partners LLC
    Petersburg, Virginia 23805, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Overall study data as required by FDAAA801 will be shared upon completion of the study.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Feb 2024, 6 months.

Results were first posted in Jan 2026, 1 year 10 months after primary completion.

Of 66 industry-sponsored phase 3 interventional studies under Attention Deficit Disorder with Hyperactivity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 19. This study's 6 months is below that.

Counting every sponsor, half of 80 studies reached it within 14 months; a quarter within 7 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2022
First posted
Mar 18, 2022
StartActual
Aug 1, 2023
Primary completionActual
Feb 29, 2024
CompletionActual
Feb 29, 2024
Results first posted
Jan 22, 2026
Last update
Jan 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05286762
Lead sponsor
Cingulate Therapeutics
Responsible party
Sponsor
First posted
Mar 18, 2022
Start date
Aug 1, 2023
Primary completion
Feb 29, 2024
Completion
Feb 29, 2024
Results posted
Jan 22, 2026
Last update
Jan 22, 2026

Study contacts

Matt Brams, MD
study director · Cingulate
Ann Childress, MD
study chair · Center for Psychiatry And Behavioral Medicine Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CTX-1301

Start the discussion